No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PBH240517P75000
- 5.11
- 0.000.00%
15min DelayClose May 10 15:57 ET
5.11High5.11Low
5.11Open5.11Pre Close1 Volume0 Open Interest75.00Strike Price511.00Turnover53.28%IV-0.48%PremiumMay 17, 2024Expiry Date4.61Intrinsic Value100Multiplier5DDays to Expiry0.50Time Value100Contract SizeAmericanOptions Type-0.8334Delta0.0572Gamma14.22Leverage Ratio-0.1000Theta-0.0072Rho-11.85Eff Leverage0.0208Vega
Intraday
- 5D
- 1D
News
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
Prestige Consumer Healthcare Inc.: John Kelly, Formerly With Pfizer, Elected to Bd. >PBH
Prestige Consumer Healthcare Inc.: John Kelly, Formerly With Pfizer, Elected to Bd. >PBH
Tatcha, Hourglass, Living Proof Power Unilever's Growth in First Quarter
Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Fanatics Aims for Explosive Growth After Completing Acquisition of PointsBet U.S.
Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well o
Comments
Investors seem to focus more on the company's revenue growth despite the decrease in earnings per share. The company's long-term track record of an annual TSR of 20% over five years makes it a business worth watching.
Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144% 1
Investors may be expecting a turnaround in the company's lackluster revenue performance, hence the moderate P/S ratio. However, the company's muted revenue growth estimates compared to the industry make its current P/S ratio unexpected. A positive change is needed to justify this ratio.
1
Prestige Consumer Healthcare's revenue growth is predicted to slow, with an estimated annual growth rate of 1.9% until 2025, significantly below the historical 4.2% p.a. growth. Compared to industry peers forecasted to grow at 9.0% per year, Prestige is expected to lag behind.
An insider selling shares below the current price may suggest they deemed the lower price fair, questioning their view of the recent higher valuation. However, this is a weak sign as it doesn't imply insiders think the shares are fully valued. The level of insider ownership indicates a reasonable alignment with shareholder interests.
Gainers:
• $Biohaven(BHVN.US$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom(VRM.US$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve(NVVE.US$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical(SWAV.US$ +14.6% (I...
• $Biohaven(BHVN.US$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $Vroom(VRM.US$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $Nuvve(NVVE.US$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ShockWave Medical(SWAV.US$ +14.6% (I...
20
2
Read more